Jazz Pharmaceuticals JAZZ EV / EBITDA

EV / EBITDA at other companies

AmgenAMGN

15.7×+0.7×

AlkermesALKS

54.7×+43.9×

Stoke Therapeutics, Inc.STOK

41.5×—

Harmony Biosciences Holdings, Inc.HRMY

5.6×-1.7×

XER

Xeris Biopharma Holdings, Inc.XERS

40.5×—

Zevra Therapeutics, Inc.ZVRA

7.9×—

FAQ

What is Jazz Pharmaceuticals's EV / EBITDA?

Jazz Pharmaceuticals (JAZZ) reported EV / EBITDA of 17.6× in Q1 2025.

How has Jazz Pharmaceuticals's EV / EBITDA changed year-over-year?

Jazz Pharmaceuticals's EV / EBITDA decreased by 18.4% year-over-year, from 21.6× to 17.6×.

What is the long-term trend for Jazz Pharmaceuticals's EV / EBITDA?

Over 3 years (2020 to 2024), Jazz Pharmaceuticals's EV / EBITDA has grown at a -19.4% compound annual growth rate (CAGR), from 28.6× to 14.9×.

What does EV / EBITDA mean?

Enterprise value (market cap plus total debt minus cash) at the quarter end divided by trailing-twelve-month EBITDA. A capital-structure-neutral valuation multiple.